Sort
8,912 grants matching “sars cov 2”
Immunoassay and Imaging Core
$226,642Stuart P Weisberg · Columbia University Health Sciences · U19 · FY2023 · AI
Development of a plant-derived virus-like particle vaccine against SARS-CoV
$226,548Brenda G Hogue · Arizona State University-Tempe Campus · R21 · FY2009 · AI
Transgenic Mouse Models for Pathogenesis and Therapy
$226,500University Of Texas Medical Br Galveston · R21 · FY2005 · AI
Blocking TMPRSS2 expression for prevention of SARS-CoV-2 infection
$226,500Houjian Cai · University Of Georgia · R21 · FY2021 · AI
Biophysical characterization of SARS-CoV-2 spike protein - receptor interactions
$226,313Wonpil Im · Lehigh University · R21 · FY2022 · AI
NON-CANONICAL MECHANISMS FOR INTERFERON-LAMBDA REGULATION OF SARS-COV-2 INFECTION
$226,254Emily Ann Hemann · Ohio State University · R21 · FY2023 · AI
Establishing Cellular Models of SARS-CoV2 Infection for COVID-19 Studies
$226,172Abraam M. Yakoub · University Of North Dakota · P20 · FY2020 · GM
Core 1: Sample Procurement and Clinical Core
$226,143John D Roback · Emory University · U54 · FY2022 · CA
Innate immune pathways underlying sexual dimorphism in obesity pathogenesis
$226,121Meera Goh Nair · University Of California Riverside · R21 · FY2024 · AI
Animal Core
$225,935Stephen Mark Tompkins · Icahn School Of Medicine At Mount Sinai · P01 · FY2025 · AI
Serological and functional impact of COVID-19 vaccination on the maternal fetal unit and infant immunity
$225,781Rupsa Chaudhury Boelig · Thomas Jefferson University · R21 · FY2022 · HD
RAPID: Linking institutional logics and data sharing to research outputs before and after SARS-CoV-2 peak infection
$225,775Eric W Welch · Arizona State University · · FY2020 · SBE
EAGER: SARS-CoV-2 Pseudovirus via a novel eukaryotic construction in yeast
$225,742Robert R Beitle · University Of Arkansas · · FY2020 · BIO
NOX1 and NOX2 as Therapeutic Targets in Influenza
$225,443J. David Lambeth · Emory University · R21 · FY2013 · AI
TASK ORDER 16: USE OF INHALED HYALURONAN IN PATIENTS WITH SEVERE COVID-19
$225,176Taharat Khan · Social And Scientific Systems, Inc. · N01 · FY2021 · ES
Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research
$225,011Cuong Q Nguyen · University Of Florida · R01 · FY2020 · DE
Peptide inhibitors of coronavirus entry
$225,000Samuel Earl Hopkins · Autoimmune Technologies, Llc · R43 · FY2014 · AI
STTR Phase I: Development and Commercialization of the SafeLight Family of Antimicrobial Materials for Combatting the COVID-19 Pandemic and Hospital Acquired Infections
$225,000Robert J Sheehan · Photocide Protection, Inc. · · FY2020 · TIP
Lateral Flow-Electrochemiluminescent (LF-ECL) Test Strips and Portable Reader for Ultrasensitive Foodborne Pathogen Detection
$225,000John Bruno · Nanohmics, Inc. · R43 · FY2022 · CK
Developing and validating serological assays to SARS-COV-2 for highly susceptible animal species
$225,000Roman Pogranichniy · Kansas State University · U18 · FY2021 · FD
Developing and validating serological assays to SARS-COV-2 for highly susceptible animal species
$225,000Roman Pogranichniy · Kansas State University · U18 · FY2022 · FD
Trimerization of the N-terminal Domain of ACE2 for Bifunctional Trapping of Future SARS-CoV-2 Variants
$224,925Rihe Liu · Univ Of North Carolina Chapel Hill · R21 · FY2021 · AI
Adjuvant effect of physical exercise on immune response to COVID-19 vaccination and interactions with stress
$224,877Marian L Kohut · Iowa State University · R21 · FY2023 · AI
Oral Microbiome, Nitric oxide Metabolism, and Oral and Cardiometabolic Health
$224,874Kaumudi J Joshipura · University Of Puerto Rico Med Sciences · R01 · FY2020 · DE
Small Molecule Screening to Identify Novel Sars-CoV-2 Therapeutics
$224,752Sara Cherry · University Of Pennsylvania · R01 · FY2021 · AI